PET2015UZ: Breast cancer preoperative 18 FDG-PET, cohort 2002-2008.

Data referred to in manuscripts:
### Breast cancer preoperative 18FDG-PET, overall survival prognostic separation
# compared with the lymph node ratio.
# Vinh-Hung V, Everaert H, Gorobets O, Van Parijs H, Verfaillie G, Vanhoeij M,
# Storme G, Fontaine C, Lamote J, Perrin J, Farid K, Nguyen NP,
# Verschraegen C, De Ridder M.
# Breast Cancer. 2021 Jul;28(4):956-968. doi: 10.1007/s12282-021-01234-z
# PMID: 33689151
#
### Is there a utility of [18F]FDG-PET before surgery in breast cancer?
# A 15-years overall survival analysis.
# Perrin, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP,
# Djassemi N, De Ridder M, Everaert H.
# World J Clin Oncol. Pending.

Code referred to in manuscript:
### Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer:
# Prognostic Value Measured with Gini’s Mean Difference of Restricted Mean Survival Times.
# Keam B, Gorobets O, Vinh-Hung V, Im SA.
# Cancer Informatics. 2021.
# doi: 10.1177/117693512110516 <== incorrect
# errata October 23, 2021, the correct DOI is:
# DOI: 10.1177/11769351211051675

File with the deidentified data: listpet2020jan31_anonym3.xlsx
The file contains SUV data for 36 patients.

Software file rankit_gmd_D-measure_04 contains R functions for use with the dataset:
rnkttb, computes scaled rankit transforms;
Dm, Royston-Sauerbrei measure of prognostic separation;
r2d, a measure of explained variation based on the D measure of separation;
r2n, Nagelkerke proportion of explained variation;
gmd, computes Gini's mean difference

文中提及的数据集：
### 乳腺癌症术前18FDG-PET，与淋巴结比率的总体生存预后分离
# 与淋巴结比率相比。
# Vinh-Hung V, Everaert H, Gorobets O, Van Parijs H, Verfaillie G, Vanhoeij M,
# Storme G, Fontaine C, Lamote J, Perrin J, Farid K, Nguyen NP,
# Verschraegen C, De Ridder M.
# 乳腺癌症. 2021年7月;28(4):956-968. doi: 10.1007/s12282-021-01234-z
# PMID: 33689151

### 术前[18F]FDG-PET在乳腺癌症中的实用性？
# 一项为期15年的总体生存分析。
# Perrin, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP,
# Djassemi N, De Ridder M, Everaert H.
# 世界临床肿瘤学杂志. 待发表。

## 文献中引用的代码：
### 新辅助化疗后II/III期乳腺癌症淋巴结比率：
# 使用Gini平均差异测量受限平均生存时间的预后价值。
# Keam B, Gorobets O, Vinh-Hung V, Im SA.
# 癌症信息学. 2021.
# doi: 10.1177/117693512110516 <== 错误
# 2021年10月23日勘误，正确的DOI为：
# DOI: 10.1177/11769351211051675

## 含脱敏数据的文件：listpet2020jan31_anonym3.xlsx
该文件包含36名患者的SUV数据。

## 包含用于数据集的R函数的软件文件rankit_gmd_D-measure_04：
rnkttb，计算缩放秩转换；
Dm，Royston-Sauerbrei预后分离度量；
r2d，基于分离度量D的解释变异度度量；
r2n，Nagelkerke解释变异比例；
gmd，计算Gini平均差异。